Hammacher Schlemmer acquired by ex-Woot leadership team
New stewards aim to restore company’s status as America’s innovation store NEW YORK, March 19, 2026 /PRNewswire/ — Stores.com announced today... Read more.
Altesa BioSciences’ Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026
Altesa advancing clinical development of vapendavir through its Phase 2B Cardinal Study COLLEGE PARK, Ga., March 19, 2026 /PRNewswire/ — Altesa BioSciences... Read more.
1stProtect Emerges from Stealth with New Approach to Endpoint Security That Stops Data Theft in Real Time
Veterans of CrowdStrike, Symantec, and Cisco Unveil Platform That Verifies User Intent and Blocks Unauthorized Data Access and Exfiltration in Microseconds—Even... Read more.
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
JERUSALEM, March 19, 2026 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation... Read more.
Bybit Introduces Yield-Bearing Gold Product Offering APR on Tokenized Gold
DUBAI, UAE, March 19, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has launched XAUT Earn, a product... Read more.
BTQ Technologies Announces First Deployment of BIP 360 on Bitcoin Quantum Testnet v0.3.0
The Bitcoin Quantum testnet provides developers, miners, and researchers with a live environment to evaluate how quantum-resistant Bitcoin transactions function... Read more.
AlphaPoint Launches Institutional-Grade Treasury Platform to Power Stablecoin and Fiat Operations at Scale
New solution enables enterprises, merchants, and financial institutions to manage liquidity, settlement, and balance sheet operations. NEW YORK, March 19, 2026 /PRNewswire/... Read more.
Biohaven’s Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in... Read more.
Soligenix Announces HyBryte™ Clinical Summary Published in “Expert Opinion on Investigational Drugs”
PRINCETON, N.J., March 19, 2026 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on... Read more.
Foundation Risk Partners and ARTDAI Announce Partnership to Deliver Best-In-Class Risk Advisory for Fine Art and Collectibles
ORMOND BEACH, Fla., March 19, 2026 /PRNewswire/ — The Private Client Practice at Foundation Risk Partners (FRP) is proud to announce a strategic nationwide... Read more.